Who
Cormorant Asset Management, LP
Other role
Company insider
Files Form 4 as: 10% owner and Other, Bright Minds Biosciences; 10% owner and Other, EyePoint; 10% owner, Corbus Pharmaceuticals Holdings; 10% owner, Ambrx Biopharma; 10% owner, Ambrx Biopharma; Director and 10% owner, Erasca; 10% owner, Biomea Fusion; Other, Pyxis Oncology.
In numbers
- Trades disclosed
- 54
- Buys
- 23
- Sells
- 2
- Bought
- $171.8M
- Sold
- $20.5M
- Companies
- 15
- Companies where not an officer
- 15
- First trade
- 9 Nov 2016
- Last trade
- 28 Apr 2026
- Last filed
- 30 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Apr 2026filed 30 Apr 2026 | DRUG Bright Minds BiosciencesBiotechnology | SEC FORM 4 Sold | $9.8M109,331 at $89.50 | filing |
| 28 Apr 2026filed 30 Apr 2026 | DRUG Bright Minds BiosciencesBiotechnology | SEC FORM 4 Sold | $9.8M109,331 at $89.50 | filing |
| 4 Dec 2025filed 8 Dec 2025 | EYPT EyePointBiotechnology | SEC FORM 4 Sold | $942K60,000 at $15.70 | filing |
| 4 Nov 2024filed 6 Nov 2024 | DRUG Bright Minds BiosciencesBiotechnology | SEC FORM 4 Bought | $4.0M184,331 at $21.70 | filing |
| 6 May 2024filed 8 May 2024 | EYPT EyePointBiotechnology | SEC FORM 4 Bought | $7.5M642,847 at $11.70 | filing |
| 6 May 2024filed 8 May 2024 | EYPT EyePointBiotechnology | SEC FORM 4 Bought | $2.6M207,153 at $12.36 | filing |
| 2 Feb 2024filed 6 Feb 2024 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Bought | $14.3M750,000 at $19.00 | filing |
| 11 Jan 2024filed 11 Jan 2024 | EYPT EyePointBiotechnology | SEC FORM 4 Bought | $14.8M750,000 at $19.75 | filing |
| 9 Jan 2024filed 11 Jan 2024 | EYPT EyePointBiotechnology | SEC FORM 4 Bought | $2.2M105,000 at $21.32 | filing |
| 8 Dec 2023filed 12 Dec 2023 | EYPT EyePointBiotechnology | SEC FORM 4 Bought | $10.0M588,235 at $17.00 | filing |
| 23 Oct 2023filed 25 Oct 2023 | Ambrx Biopharma | SEC FORM 4 Bought | $9.1M1,307,311 at $6.99 | filing |
| 18 Sep 2023filed 19 Sep 2023 | Ambrx Biopharma | SEC FORM 4 Bought | $6.9M751,233 at $9.24 | filing |
| 15 Sep 2023filed 19 Sep 2023 | Ambrx Biopharma | SEC FORM 4 Bought | $12.7M1,401,505 at $9.05 | filing |
| 13 Dec 2022filed 21 Dec 2022 | ERAS ErascaBiotechnology | SEC FORM 4 Bought | $2.0M307,692 at $6.50 | filing |
| 13 Dec 2022filed 20 Dec 2022 | ERAS ErascaBiotechnology | SEC FORM 4 Bought | $2.0M307,692 at $6.50 | filing |
| 22 Jun 2022filed 24 Jun 2022 | BMEA Biomea Fusionoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,867 at $0.00 | filing |
| 13 Oct 2021filed 15 Oct 2021 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code C | —668,854 | filing |
| 13 Oct 2021filed 15 Oct 2021 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Code C | —668,854 | filing |
| 13 Oct 2021filed 15 Oct 2021 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Bought | $7.2M450,000 at $16.00 | filing |
| 3 Aug 2021filed 5 Aug 2021 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,702,628 | filing |
News
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Jefferies Financial Group to "Hold"EYPT · tickerreport.com · 19 Oct 2026Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Up 6.6% – Here's What HappenedDRUG · themarketsdaily.com · 15 Oct 2026Critical Review: Eyepoint Pharmaceuticals (NASDAQ:EYPT) and GSK (NYSE:GSK)EYPT · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Cormorant Asset Management, LP; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.